Therapeutic Response

ER positive, HER2-positive, and PR positive status confers therapeutic sensitivity to Anastrozole in combination with Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description

Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved trastuzumab (subcutaneous - 21 days) in combination with an aromatase inhibitor as a treatment option for the treatment of HER2 positive, hormone-receptor positive metastatic breast cancer not previously treated with trastuzumab for patients who are postmenopausal. The corresponding European Medicines Agency approval for this indication cites the clinical trial BO16216 as rationale for the approval where Herceptin (trastuzumab) and anastrozole were administered.